Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nick Giannoukakis
New Jersey, United Statesdiavacs.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DiaVacs developed a cell therapy using a patient’s own dendritic cells, engineered to be tolerogenic and then re-injected, with early clinical trials demonstrating safety and signals of insulin production in Type 1 diabetes patients
- Therapeutic areas
- ImmunologyEndocrinology
- Modalities
- Dendritic cell therapyCell therapy
- Industry
- Biotech
02
Partnerships
University of Pittsburgh (manufacturing, clinical trials)
Beyond the preview
Go deeper on Nick Giannoukakis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nick Giannoukakis.